Cover Image

Biosimilars of low-molecular-weight heparin products: fostering competition or reducing ‘biodiversity’?

The term ‘biosimilars’ is used to qualify products developed to be similar to an original biological drug. Biosimilars are much more complicated to develop than a generic version of small-molecule drugs and this is especially true for low-molecular-weight heparins (LMWHs). Evidence on the antithromb...

Full description

Saved in:
Bibliographic Details
Main Author: Harenberg, Job (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: Journal of thrombosis and haemostasis
Year: 2016, Volume: 14, Issue: 3, Pages: 421-426
ISSN:1538-7836
DOI:10.1111/jth.13237
Online Access:Verlag, Volltext: https://doi.org/10.1111/jth.13237
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.13237
Get full text
Author Notes:J. Harenberg, C. Cimminiello, G. Agnelli, G. Di Minno, H. Polo Friz, P. Prandoni and F. Scaglione

MARC

LEADER 00000caa a2200000 c 4500
001 1679771086
003 DE-627
005 20230427134456.0
007 cr uuu---uuuuu
008 191024s2016 xx |||||o 00| ||eng c
024 7 |a 10.1111/jth.13237  |2 doi 
035 |a (DE-627)1679771086 
035 |a (DE-599)KXP1679771086 
035 |a (OCoLC)1341249218 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Harenberg, Job  |d 1950-  |e VerfasserIn  |0 (DE-588)108825507  |0 (DE-627)655891498  |0 (DE-576)339563745  |4 aut 
245 1 0 |a Biosimilars of low-molecular-weight heparin products  |b fostering competition or reducing ‘biodiversity’?  |c J. Harenberg, C. Cimminiello, G. Agnelli, G. Di Minno, H. Polo Friz, P. Prandoni and F. Scaglione 
264 1 |c 2016 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 24.10.2019 
500 |a First published: 29 December 2015 
520 |a The term ‘biosimilars’ is used to qualify products developed to be similar to an original biological drug. Biosimilars are much more complicated to develop than a generic version of small-molecule drugs and this is especially true for low-molecular-weight heparins (LMWHs). Evidence on the antithrombotic management of acute coronary syndromes (ACS) showed that the introduction into the market of biosimilars approved on the basis of simple biological criteria, without robust data from comparative clinical trials, may be hazardous. Moreover, the mixtures of LMWH polysaccharide chains, some immunoallergic properties and potential contamination during the extraction process raise safety concerns. As was the case for the biosimilar erythropoietin, there is the risk that only copies of the most commercially successful LMWHs will be marketed, thus jeopardizing the ‘biodiversity’ now ensured by the presence of several LMWHs, each with unique features that support the use of an individual LMWH as first-choice therapy in certain categories of patients. 
650 4 |a biosimilar pharmaceuticals 
650 4 |a evidence-based practise 
650 4 |a low-molecular-weight heparin 
650 4 |a therapeutic equivalency 
650 4 |a venous thromboembolism 
773 0 8 |i Enthalten in  |t Journal of thrombosis and haemostasis  |d [Amsterdam] : Elsevier, 2003  |g 14(2016), 3, Seite 421-426  |h Online-Ressource  |w (DE-627)361297211  |w (DE-600)2099291-9  |w (DE-576)103373810  |x 1538-7836  |7 nnas  |a Biosimilars of low-molecular-weight heparin products fostering competition or reducing ‘biodiversity’? 
773 1 8 |g volume:14  |g year:2016  |g number:3  |g pages:421-426  |g extent:6  |a Biosimilars of low-molecular-weight heparin products fostering competition or reducing ‘biodiversity’? 
856 4 0 |u https://doi.org/10.1111/jth.13237  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.13237  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20191024 
993 |a Article 
994 |a 2016 
998 |g 108825507  |a Harenberg, Job  |m 108825507:Harenberg, Job  |d 60000  |e 60000PH108825507  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1679771086  |e 3526995435 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Harenberg, Job","roleDisplay":"VerfasserIn","role":"aut","family":"Harenberg","given":"Job"}],"title":[{"subtitle":"fostering competition or reducing ‘biodiversity’?","title":"Biosimilars of low-molecular-weight heparin products","title_sort":"Biosimilars of low-molecular-weight heparin products"}],"language":["eng"],"recId":"1679771086","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 24.10.2019","First published: 29 December 2015"],"name":{"displayForm":["J. Harenberg, C. Cimminiello, G. Agnelli, G. Di Minno, H. Polo Friz, P. Prandoni and F. Scaglione"]},"id":{"doi":["10.1111/jth.13237"],"eki":["1679771086"]},"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"relHost":[{"origin":[{"publisherPlace":"[Amsterdam] ; Oxford ; Oxford","dateIssuedKey":"2003","publisher":"Elsevier ; Blackwell Publishing ; Wiley-Blackwell","dateIssuedDisp":"2003-"}],"id":{"issn":["1538-7836"],"doi":["10.1111/(ISSN)1538-7836"],"eki":["361297211"],"zdb":["2099291-9"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"the official journal of the International Society on Thrombosis and Haemostasis","title":"Journal of thrombosis and haemostasis","title_sort":"Journal of thrombosis and haemostasis"}],"pubHistory":["1.2003 -"],"titleAlt":[{"title":"jth"}],"part":{"year":"2016","issue":"3","pages":"421-426","text":"14(2016), 3, Seite 421-426","volume":"14","extent":"6"},"disp":"Biosimilars of low-molecular-weight heparin products fostering competition or reducing ‘biodiversity’?Journal of thrombosis and haemostasis","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 16.02.2023"],"corporate":[{"role":"isb","display":"International Society on Thrombosis and Haemostasis","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"recId":"361297211"}],"physDesc":[{"extent":"6 S."}]} 
SRT |a HARENBERGJBIOSIMILAR2016 

Similar Items